Takeda calls time on ramelteon in Europe

Takeda has finally decided to discontinue the development of its insomnia drug ramelteon in the EU following the withdrawal of an approval filing in this market back in September 2008, in the wake of a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).

Takeda has finally decided to discontinue the development of its insomnia drug ramelteon in the EU following the withdrawal of an approval filing in this market back in September 2008, in the wake of a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).

A submission for 4mg and 8mg tablets of the melatonin MT1 and MT2 receptor agonist had been made under the...

More from Alimentary/Metabolic

More from Therapeutic Category

Sanofi Doubles Down On Respiratory Vaccines With Vicebio Buy

 
• By 

The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results

 

The biotech company is planning for Phase III based on positive topline results from Vibrance-1 in narcolepsy type 1 and remains optimistic about type 2 disease.

After Gilead Deal, Hookipa Hangs Up Its Hat

 
• By 

The Austrian firm is delisting from the NASDAQ and closing down.